Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Lipid Suspension vs Conventional Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT06867562Phase 3Not yet recruiting
- Sponsor
- Jina Pharmaceuticals, Inc.
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of paclitaxel in Serous Epithelial Ovarian Cancer (SOC), fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Jina Pharmaceuticals, Inc.. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
Serous Epithelial Ovarian Cancer (SOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT06867562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867562.